Prot #CPI 0610-04: A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients (MANIFEST-2)

Project: Research project

Project Details

StatusActive
Effective start/end date7/26/21 → 7/26/24

Funding

  • Novella Clinical, LLC (Prot#CPI 0610-04)
  • Constellation Pharmaceuticals, Inc. (Prot#CPI 0610-04)